Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 28, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Corporate Review

NEW YORK and MELBOURNE, Australia, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine...
December 24, 2018 06:30 ET | Source: Mesoblast Limited

Mesoblast to Present at 2019 Biotech Showcase in San Francisco

NEW YORK and MELBOURNE, Australia, Dec. 24, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) will report on its Phase 3 trials and commercial plans at the upcoming Biotech Showcase...
December 19, 2018 07:22 ET | Source: Mesoblast Limited

Mesoblast Makes Executive Appointment to Drive Product Commercialization

NEW YORK and MELBOURNE, Australia, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that it has appointed Eric Strati, PhD, to the new position of Senior...
December 13, 2018 06:00 ET | Source: Mesoblast Limited

Meetings Held With FDA Support Mesoblast’s Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD

NEW YORK and MELBOURNE, Australia, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that recent meetings held with the United States Food and Drug...
November 26, 2018 06:00 ET | Source: Mesoblast Limited

Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China

NEW YORK and MELBOURNE, Australia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the first Joint Steering Committee...
November 15, 2018 16:33 ET | Source: Mesoblast Limited

Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights

MELBOURNE, Australia and NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported strong financial results and provided operational highlights for the...
November 15, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018

NEW YORK and MELBOURNE, Australia, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended September 30, 2018 in a webcast...
November 11, 2018 19:59 ET | Source: Mesoblast Limited

Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval

NEW YORK and MELBOURNE, Australia, Nov. 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that results from a 159-patient randomized, sham-controlled Phase 2...
November 09, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions

NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its...
October 24, 2018 06:05 ET | Source: Mesoblast Limited

Mesoblast Expands Partnership With JCR Pharmaceuticals for Treatment of Wound Healing in Epidermolysis Bullosa

NEW YORK and MELBOURNE, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd. in...